Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice.
| Title: | Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice. |
|---|---|
| Authors: | O'Tousa DS; Department of Psychology, Indiana University-Purdue University, Indianapolis, IN, USA.; Warnock KT; Matson LM; Namjoshi OA; Linn MV; Tiruveedhula VV; Halcomb ME; Cook J; Grahame NJ; June HL |
| Source: | Addiction biology [Addict Biol] 2015 Mar; Vol. 20 (2), pp. 236-47. Date of Electronic Publication: 2013 Oct 13. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Language: | English |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 9604935 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1369-1600 (Electronic) Linking ISSN: 13556215 NLM ISO Abbreviation: Addict Biol Subsets: MEDLINE |
| Imprint Name(s): | Publication: Hoboken, NJ : Wiley-Blackwell; Original Publication: Abingdon, Oxfordshire, UK ; Cambridge, MA : Carfax, c1996- |
| MeSH Terms: | Alcohol Drinking* ; Binge Drinking*; Adrenergic Uptake Inhibitors/*pharmacology ; Aza Compounds/*pharmacology ; Behavior, Animal/*drug effects ; Bridged Bicyclo Compounds, Heterocyclic/*pharmacology ; Dopamine Uptake Inhibitors/*pharmacology ; Impulsive Behavior/*drug effects ; Selective Serotonin Reuptake Inhibitors/*pharmacology; Carbolines/pharmacology ; Animals ; Mice |
| Abstract: | Approximately 30% of current drinkers in the United States drink excessively, and are referred to as problem/hazardous drinkers. These individuals, who may not meet criteria for alcohol abuse or dependence, comprise binge, heavy drinkers, or both. Given their high prevalence, interventions that reduce the risk of binge and heavy drinking have important public health implications. Impulsivity has been repeatedly associated with excessive drinking in the clinical literature. As impulsivity is correlated with, and may play a critical role in, the initiation and maintenance of excessive drinking, this behavior may be an important target for therapeutic intervention. Hence, a better understanding of pharmacological treatments capable of attenuating excessive drinking and impulsivity may markedly improve clinical outcomes. The high-alcohol-preferring (HAP) mice represent a strong rodent model to study the relationship between impulsivity and excessive alcohol drinking, as recent evidence indicates they consume high levels of alcohol throughout their active cycle and are innately impulsive. Using this model, the present study demonstrates that the triple monoamine uptake inhibitors (TUIs) amitifadine and DOV 102, 677 effectively attenuate binge drinking, heavy drinking assessed via a 24-hour free-choice assay, and impulsivity measured by the delay discounting procedure. In contrast, 3-PBC, a GABA-A α1 preferring ligand with mixed agonist-antagonist properties, attenuates excessive drinking without affecting impulsivity. These findings suggest that in HAP mice, monoamine pathways may predominate as a common mechanism underlying impulsivity and excessive drinking, while the GABAergic system may be more salient in regulating excessive drinking. We further propose that TUIs such as amitifadine and DOV 102, 677 may be used to treat the co-occurrence of impulsivity and excessive drinking.; (© 2013 Society for the Study of Addiction.) |
| References: | J Exp Anal Behav. 1972 Jan;17(1):15-22. (PMID: 16811561); CNS Neurol Disord Drug Targets. 2007 Apr;6(2):141-9. (PMID: 17430151); Neuropsychopharmacology. 2006 Feb;31(2):351-62. (PMID: 15957006); Alcohol Clin Exp Res. 2010 Aug;34(8):1334-45. (PMID: 20491733); Nature. 2010 Dec 23;468(7327):1061-6. (PMID: 21179162); J Pharmacol Exp Ther. 2000 Oct;295(1):51-7. (PMID: 10991960); Psychopharmacology (Berl). 1999 Oct;146(4):447-54. (PMID: 10550495); Nonlinearity Biol Toxicol Med. 2005 Jan;3(1):9-21. (PMID: 19330154); Med J Aust. 2001 Mar 19;174(6):281-4. (PMID: 11297115); Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4465-70. (PMID: 21368176); Neuropsychopharmacology. 2012 Aug;37(9):2057-66. (PMID: 22510726); J Psychiatr Res. 2012 Jan;46(1):64-71. (PMID: 21925682); JAMA. 2003 Jan 1;289(1):70-5. (PMID: 12503979); Genes Brain Behav. 2008 Oct;7(7):705-13. (PMID: 18518928); Sci Signal. 2008 Jul 15;1(28):re7. (PMID: 18632551); Neurosci Biobehav Rev. 2000 Jan;24(1):31-9. (PMID: 10654658); J Exp Psychol Gen. 1999 Mar;128(1):78-87. (PMID: 10100392); J Exp Anal Behav. 1997 May;67(3):353-66. (PMID: 9163939); Pharmacol Biochem Behav. 2012 Nov;103(1):111-8. (PMID: 22884707); Psychopharmacology (Berl). 2001 Mar;154(3):243-50. (PMID: 11351931); Synapse. 2012 May;66(5):435-44. (PMID: 22213370); Neuropsychopharmacology. 2007 Jan;32(1):137-52. (PMID: 16710315); Drug Alcohol Depend. 2013 Jan 1;127(1-3):150-5. (PMID: 22818514); J Neurosci. 2002 May 1;22(9):3765-75. (PMID: 11978852); Psychopharmacology (Berl). 2012 Jan;219(2):401-10. (PMID: 22101355); Biochem Pharmacol. 2008 Jan 1;75(1):34-56. (PMID: 17880925); Arch Gen Psychiatry. 2011 Apr;68(4):389-99. (PMID: 21464363); Alcohol Clin Exp Res. 2009 Jul;33(7):1294-303. (PMID: 19389183); Behav Genet. 2012 Mar;42(2):313-22. (PMID: 21989731); Alcohol Clin Exp Res. 2012 May;36(5):863-73. (PMID: 22150508); Neuropsychopharmacology. 2011 Jun;36(7):1518-30. (PMID: 21430652); Addict Biol. 2013 Nov;18(6):921-9. (PMID: 22126215); Psychopharmacology (Berl). 2006 Oct;188(2):162-70. (PMID: 16915378); Alcohol Clin Exp Res. 2005 May;29(5):902-8. (PMID: 15897737); Methods Find Exp Clin Pharmacol. 1981 Sep-Oct;3(5):291-6. (PMID: 7329157); Neuropsychopharmacology. 2007 Feb;32(2):439-49. (PMID: 17047667); Prev Chronic Dis. 2006 Apr;3(2):A53. (PMID: 16539794); Pharmacol Rev. 2007 Dec;59(4):360-417. (PMID: 18160701); Alcohol Clin Exp Res. 2008 Sep;32(9):1681-7. (PMID: 18631324); Neuropsychopharmacology. 2004 Jul;29(7):1331-43. (PMID: 15054475); Alcohol Clin Exp Res. 2010 Aug;34(8):1363-75. (PMID: 20491739); Crit Rev Neurobiol. 1998;12(4):339-69. (PMID: 10348615); Neuroscience. 2012 Jul 26;215:42-58. (PMID: 22542672); Psychol Bull. 2009 Jan;135(1):142-56. (PMID: 19210057); Curr Protoc Neurosci. 2010 Apr;Chapter 9:Unit 9.12.1-26. (PMID: 20373508); J Abnorm Child Psychol. 1995 Apr;23(2):235-66. (PMID: 7642836); Addict Biol. 2010 Apr;15(2):217-26. (PMID: 20148781); J Pharmacol Exp Ther. 2007 Feb;320(2):757-65. (PMID: 17105829); J Pharmacol Exp Ther. 2008 Mar;324(3):1111-26. (PMID: 18089843); Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):857-73. (PMID: 16636898); Front Neurosci. 2011 Oct 18;5:123. (PMID: 22022305) |
| Grant Information: | R01 MH096463 United States MH NIMH NIH HHS; AA017611 United States AA NIAAA NIH HHS; R24 AA015512 United States AA NIAAA NIH HHS; R01 MH046851 United States MH NIMH NIH HHS; P60 AA007611 United States AA NIAAA NIH HHS; T32 AA007462 United States AA NIAAA NIH HHS; R01 HL118561 United States HL NHLBI NIH HHS; AA10406 United States AA NIAAA NIH HHS; R01 NS076517 United States NS NINDS NIH HHS; R01 AA010406 United States AA NIAAA NIH HHS; R43 MH083417 United States MH NIMH NIH HHS; U24 AA015512 United States AA NIAAA NIH HHS; AA015512 United States AA NIAAA NIH HHS |
| Contributed Indexing: | Keywords: Alcohol use disorders; HAP mice; delay discounting; impulsivity; triple uptake inhibitor |
| Substance Nomenclature: | 0 (Adrenergic Uptake Inhibitors); 0 (Aza Compounds); 0 (Bridged Bicyclo Compounds, Heterocyclic); 0 (Carbolines); 0 (Dopamine Uptake Inhibitors); 0 (Selective Serotonin Reuptake Inhibitors); 0 (1-(3,4-dichlorophenyl)-3-azabicyclo-(3.1.0)hexane hydrochloride); 0 (3-propoxy-beta-carboline); 0 (DOV 102,677) |
| Entry Date(s): | Date Created: 20131015 Date Completed: 20151021 Latest Revision: 20260128 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC3984927 |
| DOI: | 10.1111/adb.12100 |
| PMID: | 24118509 |
| Database: | MEDLINE |
Journal Article; Research Support, N.I.H., Extramural